Understanding the impact of screening and treating liver disease in diabetes patients
Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients
This study is looking at how common non-alcoholic fatty liver disease is in people with type 2 diabetes and aims to find better ways to spot and treat it, so that patients can live healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Foundation NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10907533 on NIH RePORTER |
What this research studies
This research investigates the prevalence and impact of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2D). It aims to develop screening guidelines and treatment strategies to identify and manage NAFLD effectively, as it affects a significant portion of T2D patients. The study will analyze the cost-effectiveness of various treatment options, including existing medications and new therapies currently in trials, to help inform clinical decisions. By focusing on early intervention, the research seeks to improve patient outcomes and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes, particularly those who may also have or be at risk for non-alcoholic fatty liver disease.
Not a fit: Patients without type 2 diabetes or those who do not have non-alcoholic fatty liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better screening and treatment options for patients with type 2 diabetes who also have non-alcoholic fatty liver disease.
How similar studies have performed: Previous research has shown promising results in managing non-alcoholic fatty liver disease in diabetes patients, but this specific approach to screening and cost-effectiveness is relatively novel.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Foundation — Cleveland, United States (Active)
Researchers
- Principal investigator: Rothberg, Michael B — Cleveland Clinic Foundation
- Study coordinator: Rothberg, Michael B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.